Risankizumab-RZAA

Graham Heap, MD, PhD, formerly Vice President and Program Leader for Takeda's global TYK2 immunology franchise, appointed President, Research and Development Also appointed: Ezequiel Neimark, MD, Head of Clinical Development; Taylor Spector, PhD, Head of Medical Affairs; Scott Stirn, DSc, Head of CMC cAMPfield Therapeutics is advancing prifemilast, a once-daily oral PDE4 inhibitor, for the treatment of inflammatory bowel disease (IBD) into global Phase 2 trials in moderate-to-severe ulcerative colitis and Crohn's disease SAN DIEGO, Aug. 3, 2026 /PRNewswire/ -- cAMPfield Therapeutics, Inc. (cAMPfield), a clinical-stage biopharmaceutical company formed to develop well-tolerated and highly effective oral medicines for immune-mediated inflammatory diseases, today announced key executive appointments to its senior leadership team. Continue Reading Graham Heap Graham Heap, MD, PhD joins as President, Research and Development (R&D), with responsibility for leading all the Company's research and development activities. Ezequiel Neimark, MD joins as Head of Clinical Development and will lead clinical execution for the prifemilast program in ulcerative colitis (UC) and Crohn's disease (CD). Taylor Spector, PhD joins as Head of Medical Affairs and will lead medical strategy, evidence generation, scientific communications, and external engagement. Scott Stirn, DSc joins as Head of Chemistry, Manufacturing, and Controls (CMC) and will lead drug substance and drug product development, manufacturing scale-up, analytical development, and clinical supply of prifemilast. These appointments deepen cAMPfield's leadership bench as the company advances prifemilast, a potentially best-in-class once-daily oral PDE4 inhibitor, into global Phase 2 trials in moderate-to-severe UC and CD. "Building a world-class leadership team with a proven track record of developing therapies for immune-mediated diseases is critical to our success," said Bill Gerhart, Chief Executive Officer of cAMPfield. "Graham, Ezequiel, Taylor, and Scott each bring deep expertise in inflammatory disease drug development and share our passionate belief that patients with IBD need better oral treatment options. Their considerable experience and leadership will be instrumental as we advance prifemilast through global Phase 2 development and position cAMPfield as a leader in IBD." "The treatment landscape for IBD continues to evolve, yet many patients still do not achieve durable disease control with existing therapies," said Dr. Heap. "I've long believed the potential of the PDE4 pathway has been underappreciated in IBD. Prifemilast combines a differentiated mechanism with encouraging clinical data, and I believe it can become an important new oral treatment option for patients with IBD. I look forward to working with the team to advance its development and to help build a broader pipeline beyond it." In addition to these appointments, cAMPfield's leadership team includes other accomplished executives building the company's technical, operational, clinical, and regulatory foundation. Patricia Turney, MBA, Chief Technical Officer, leads technical operations and manufacturing, bringing prior experience from Acelyrin, Arcutis, and Amgen. John Kempen, MS, Senior Vice President of Clinical Development Operations, oversees clinical execution for the prifemilast program, drawing on prior experience from Gossamer Bio, Receptos/Celgene, Ardea Biosciences/AstraZeneca, Allergan, PPD, and ICON. Rita Shah, PharmD, Vice President of Regulatory Affairs, directs the company's global regulatory strategy, leveraging prior experience from Vertex Pharmaceuticals, MBX Biosciences, AstraZeneca, and Johnson & Johnson. Biographies Graham Heap, MD, PhD – President, R&D A physician-scientist with an academic foundation in IBD and extensive development experience across gastroenterology, dermatology and rheumatology, Dr. Heap brings broad leadership expertise advancing therapies for immune-mediated diseases. Most recently, he served as Vice President and Program Leader for Takeda's global TYK2 immunology franchise, leading a large global cross-functional organization responsible for the strategy and execution of a late-stage development portfolio spanning six immune-mediated disease indications. He led zasocitinib from program integration through Phase 2 and Phase 3 readouts, including head-to-head trials against multiple comparators, while expanding the portfolio into five additional indications in Phase 2 or Phase 3 development. Prior to Takeda, Dr. Heap advanced multiple immunology and UC development programs at AbbVie, including risankizumab and ravagalimab. He earned his MBBS from St. George's, University of London and his PhD from Barts and The London School of Medicine and Dentistry. Ezequiel Neimark, MD – Vice President, Head of Clinical Development During more than a decade at AbbVie, Dr. Neimark held senior development leadership roles across gastroenterology, dermatology, and rheumatology and contributed to multiple pivotal IBD programs with adalimumab and risankizumab. He most recently served as Head of Asset/Indication for Skyrizi®, Humira®, ABBV-547, and ABBV-423, and is a physician-scientist trained in gastroenterology and hepatology. Taylor Spector, PhD – Executive Director, Head of Medical Affairs Dr. Spector brings nearly 15 years of Medical Affairs experience across all stages of the product lifecycle advancing programs in immune-mediated inflammatory diseases. Most recently she served as Global Medical Lead for Takeda's TYK2 program in Dermatology. Previously, she held Medical Affairs and Commercial leadership roles at Sobi, Alexion Pharmaceuticals, Sage Therapeutics, Amarin, and AstraZeneca. Scott Stirn, DSc – Executive Director, Head of CMC Dr. Stirn brings over two decades of experience advancing the product development and manufacturing of small molecules, peptides, and biologics from discovery through clinical development. Most recently, as Director and Head of Early Phase Product Development at Neurocrine Biosciences, he served as a global program and CMC lead across multiple small-molecule, peptide, and gene therapy programs, and contributed to the CMC regulatory filings supporting approved therapies including Ingrezza® (valbenazine) and Crenessity® (crinecerfont). Earlier in his career, he led formulation and product development efforts at Pharmatek, Celgene, and Arena Pharmaceuticals, spanning oral and injectable programs—including the development of lorcaserin (Belviq®) and S1P receptor modulator assets. About Inflammatory Bowel Disease Inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, is a chronic immune-mediated inflammatory disease that affects more than 2.4 million people in the United States and remains an area of substantial unmet medical need. Despite significant advances in treatment, many patients fail to achieve durable remission or lose response over time, resulting in frequent treatment switching. While biologic therapies have transformed outcomes for many patients, there remains a need for additional effective, well-tolerated treatment options. Convenient oral therapies are an important part of the treatment landscape, yet currently approved oral agents for IBD are limited by tolerability, safety concerns and/or modest efficacy. About Prifemilast Prifemilast is an investigational, once-daily, PDE4B-selective inhibitor that has been studied in more than 700 participants to date, including more than 250 participants treated for up to 52 weeks. Prifemilast preferentially inhibits PDE4B, the isoform most closely associated with anti-inflammatory activity, while minimizing inhibition of PDE4D, an isoform associated with dose-limiting adverse effects. Across clinical studies, prifemilast has been well tolerated, with treatment discontinuation rates comparable to placebo, and with demonstrated efficacy thus far in Phase 3 clinical trials in plaque psoriasis. About cAMPfield Therapeutics cAMPfield Therapeutics is a clinical-stage biopharmaceutical company focused on developing well-tolerated and highly effective oral medicines for immune-mediated inflammatory diseases, including inflammatory bowel disease. cAMPfield was founded by Mountainfield Venture Partners in partnership with executives who played key roles in the development and/or commercialization of Entyvio®, Humira®, Otezla®, and Zeposia®. cAMPfield holds exclusive global development and commercialization rights to prifemilast outside Greater China through a license agreement with Newsoara Biopharma Co., Ltd. The company is headquartered in San Diego, California. For more information, visit . Media and Investor Contact Rayne Rodgers [email protected] cAMPfield Therapeutics All third-party product names, company names, and logos are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them. SOURCE cAMPfield Therapeutics 21% more press release views with Request a Demo

BFC Group简介 BFC Group是一家立足于中国的精品投行，专注于医疗健康领域的并购、专利许可、融资。我们的业务板块涉及中国、美国和欧洲，曾与国内外众多领先的医疗健康公司有过合作并保持着良好的关系。随着在美国和中国一线运营经验的不断积累，我们对客户在本土之外建立公司或扩展业务所面临的挑战有着深刻的理解。 立于塔顶，高瞻之见。 使命愿景 紧跟医疗健康领域趋势，通过合作推动科学突破与创新。 依客户需求制定战略拓展计划，并在目标市场全方位落实与执行。 成为专注医疗健康行业最优秀的投资银行。 No.1 香港资本市场 香港股市总体概览 7月31日，香港统计处公布二季度本地生产总值预估同比实质增长4.3%，较首季5.9%放缓；货物出口增长28.8%，私人消费增长2.9%，季调环比下降0.6%，外部地缘及货币政策不确定性仍受关注。 上周，恒生指数上涨3.7%。2026年至今，恒生数累计下跌1.0%。 上周，恒生医疗保健指数(HSHCI) 下跌1.4%。 7月27日，石药集团宣布盐酸阿姆西汀肠溶片（HA1406）治疗抑郁症患者的III期注册性临床试验达到主要终点。结果显示，第8周末HA1406组MADRS评分较基线变化显著优于安慰剂（P<0.0001），且疗效数值上优于阳性对照药。详细数据计划于近期国际学术会议披露。该结果支持HA1406进一步推进注册申报，并有望成为石药集团在CNS领域的重要商业化资产。HA1406定位于成熟抗抑郁药市场，通过优化SNRI类药物疗效与耐受性，有望与现有SSRIs/SNRIs形成差异化竞争。 2026年至今，医药板块落后大盘，恒生医疗保健指数累计下跌5.7%，落后恒生指数6.7个百分点。 香港股市医疗健康板块概览 上周，恒生医疗保健指数市值前20个股涨跌不一。 7月27日，思路迪医药宣布与SELLAS Life Sciences围绕3D189（一款靶向WT1抗原的多肽肿瘤免疫治疗药物）许可协议纠纷的香港国际仲裁获得终局裁决。2020年12月，思路迪从SELLAS引进3D189在大中华地区的独家开发及商业化权益。后续双方因3D189进入III期临床阶段后相关里程碑付款触发条件及协议义务履行产生争议，SELLAS于2023年向香港国际仲裁中心提起仲裁。最终，仲裁员驳回SELLAS全部仲裁请求，并裁定其承担约798.3万港元仲裁成本。 香港股市医疗健康板块证券发行 2026年截至目前，共15家企业上市(其中9家为依照18A新规上市的未盈利生物药公司)，数量较去年上涨7.1%，金额总数上落后去年同期23%。 上周无新增IPO。 2026年至今，共有29家企业完成定增，数量落后去年同期23.7%，金额总数上落后去年同期70.8%。 上周无新增定增。 香港股市医疗健康板块IPO动态 港股医疗板块拟上市企业 No.2 沪深资本市场 沪深股市总体股市概览 上周，上证指数上涨0.5%，沪深300下跌1.3%。 7月27日，国家统计局公布，上半年规模以上工业企业利润总额39479.9亿元，同比增长18.7%；其中制造业利润增长20.1%，私营企业利润增长13.0%，营收利润率升至5.70%，工业盈利总体改善。 上周，上证医药上涨1.4%，医药中信指数上涨2.7%。 7月28日，国家医保局公布第十二批国家药品集采通过信息审核企业及全国需求量，企业联合申报承诺和供应清单于7月29日截止，品种材料打印窗口于7月31日上午结束，本批集采进入企业申报与报价准备阶段。 沪深股市医疗健康板块概览 医药中信指数2026年7月累计上涨4.9%。上周市值前20个股涨跌不一。 7月28日，诺诚健华宣布其自主研发的新型口服TYK2抑制剂Fadeucravacitinib（ICP-488）治疗中重度斑块状银屑病的III期注册性临床试验达到主要终点，并在多项次要疗效指标中取得一致性积极结果，安全性与既往研究结果一致。公司计划基于该III期结果推进后续注册申报，有望进一步拓展其在自身免疫疾病领域的商业化布局。ICP-488是诺诚健华布局自身免疫领域的重要核心资产，其通过选择性靶向TYK2-JH2假激酶结构域，抑制IL-12/IL-23及I型干扰素信号通路，旨在兼顾口服便利性与JAK抑制剂相关安全风险降低。 沪深股市医疗健康板块概览 上周，创新药指数下跌0.5%，医疗器械指数上涨4.9%。 7月27日，百利天恒宣布自主研发HER2 ADC注射用T-Bren（BL-M07D1）用于HER2表达的含铂化疗失败局部晚期或转移性胆道癌患者的III期试验完成首例入组。该研究旨在评价T-Bren相比医生选择化疗方案在既往含铂治疗失败HER2表达胆道癌患者中的疗效和安全性。T-Bren目前已在乳腺癌、胃癌、肺癌及胆道癌等多个HER2相关瘤种开展临床开发。 沪深股市医疗健康板块新股发行 2026年截至目前，共有1家企业上市。 上周无新增IPO。 2026年至今，共有5家企业完成定增6项，其中奥浦迈为2项。 上周无新增定增。 沪深股市医疗健康板块IPO动态 沪深股市医疗板块IPO排队企业情况 No.3 NASDAQ 美国股市总体股市概览 上周美股三大指数全线收涨，纳指累计上涨1.59%、标普500上涨1.05%、道指上涨1.04%；周中波动剧烈，周三受挫后周四随即反弹。 2026年截至目前纳指累计上涨9.2%。 上周纳斯达克生物技术指数 (NBI)下跌涨0.6%。 7月31日，艾伯维公布了2026H1业绩，上半年总营收319.92亿美元，同比增长11.2%。免疫、神经科学、肿瘤、美容以及其他类业务五大板块分别收入160.76亿美元（+15.7%）、61.03亿美元（+22.9%）、32.81亿美元（-0.9%）、24.68亿美元（+3.7%）、19.30亿美元（+4.5%）。Skyrizi表现瞩目，上半年销售额达到99.88亿美元（+27.3%），与Rinvoq（乌帕替尼）合计销售额达到146.32亿美元，占免疫业务收入91%，占公司总营收46%。 2026年截至目前，NBI累计涨13.1%，领先纳指3.9%。 美国股市医疗健康板块概览 2025年总体，纳斯达克生物技术指数 (NBI)上半年较为波动，下半年涨势迅猛，2026年前2个月NBI上行，3月NBI回落3.3%，5至6月持续回升，7月小幅回落。 7月30日，Regeneron公布2026年二季度业绩，实现总收入42.91亿美元，同比增长17%；非GAAP每股收益14.29美元。核心产品持续驱动增长，其中与Sano覅合作分成的Dupixent全球销售额同比增长38%至约60亿美元，受益于特应性皮炎、哮喘、慢性鼻窦炎伴鼻息肉等多个适应症持续放量；眼科产品EYLEA HD美国销售额同比增长52%至5.96亿美元。公司增长主要依赖Dupixent和EYLEA HD两大商业化资产，同时公司持续推进免疫、眼科、肿瘤及代谢领域研发管线布局。 美国股市医疗健康板块新股发行 2025年全年，NGS&NGM医疗健康板块共有19支新股发行，累计募资102.5亿美元；其中包括8支生物医药新股，累计募资超15亿美元。2026年截至目前，共有18支新股发行，数量较去年同期上升38.5%，金额同比增长132.4%。 上周新增IPO一家。7月31日，Apnimed（APMD）完成NASDAQ GM IPO，发行1,200万股普通股，发行价16 USD/股，募集资金约1.92亿USD。公司是一家临床后期睡眠疾病药物开发公司，核心管线AD109为固定剂量复方药物，由去甲肾上腺素再摄取抑制剂atomoxetine与抗胆碱药aroxybutynin组成，通过增强睡眠期间上气道神经肌肉活性改善阻塞性睡眠呼吸暂停。AD109已完成两项III期临床研究，并向FDA提交NDA申请，目标成为OSA领域首批口服药物治疗方案之一。计划利用IPO募集资金支持AD109商业化准备及后续睡眠障碍适应症拓展。IPO由BofA Securities, Inc.,Evercore Group L.L.C.,Cantor Fitzgerald & Co.,LifeSci Capital LLC担任主承销商。 2025年美国医疗健康板块共有316家企业完成定增，累计募资195.7亿美元。2026年伊始，截至目前有154家企业完成定增，数量上同比去年减少16.8%，金额较去年同期上涨185.7%。 上周共有2起新增定增，其中募资金额最高的是INOVIO PHARMACEUTICALS，总募集金额2千万美元。 医疗健康板块IPO动态 No.4 近期融资事件